Jerry C Rosenberg - Comment

Document ID: FDA-2011-D-0305-0012
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: July 31 2011, at 12:00 AM Eastern Daylight Time
Date Posted: September 8 2011, at 12:00 AM Eastern Standard Time
Comment Start Date: June 1 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: August 30 2011, at 11:59 PM Eastern Standard Time
Tracking Number: 80ed1834
View Document:  View as format xml

View Comment

One cannot doubt that the FDA serves an essential role in protecting the people of the Unied States from unintended commercial misadventures as well as outright fraudulent practices. We support and endorse their goals and congratulate them for all the good they do. But it is inevitable that their judgement is not infallible, as this draft guidline indicates. It purports to protect but its true effect will do more harm than good. We need to be able to carry out unfettered research. That will result in the data that will allow the FDA. as well as the health care porfession. to make reasoned fact-based ddecisions. I support the FDA, but i do not support this guideline: I strongly oppose it.

Related Comments

    View All
Total: 48
American Association for Clinical Chemistry (AACC) - Comment
Public Submission    Posted: 08/26/2011     ID: FDA-2011-D-0305-0006

Aug 30,2011 11:59 PM ET
Celera Corporation and Focus Diagnostics, Inc. - Comment
Public Submission    Posted: 08/26/2011     ID: FDA-2011-D-0305-0007

Aug 30,2011 11:59 PM ET
Wadsworth Center, New York State Dept Health - Comment
Public Submission    Posted: 09/08/2011     ID: FDA-2011-D-0305-0008

Aug 30,2011 11:59 PM ET
Neng Yu - Comment
Public Submission    Posted: 09/08/2011     ID: FDA-2011-D-0305-0010

Aug 30,2011 11:59 PM ET
Lucie Richard - Comment
Public Submission    Posted: 09/08/2011     ID: FDA-2011-D-0305-0011

Aug 30,2011 11:59 PM ET